>
Switch to:

Keros Therapeutics Cash-to-Debt

: 320.21 (As of Mar. 2021)
View and export this data going back to 2020. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Keros Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2021 was 320.21.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Keros Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2021.

NAS:KROS' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.51   Med: 132.5   Max: 320.21
Current: 320.21

5.51
320.21

During the past 3 years, Keros Therapeutics's highest Cash to Debt Ratio was 320.21. The lowest was 5.51. And the median was 132.50.

NAS:KROS's Cash-to-Debt is ranked higher than
81% of the 1395 Companies
in the Biotechnology industry.

( Industry Median: 12.01 vs. NAS:KROS: 320.21 )

Keros Therapeutics Cash-to-Debt Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keros Therapeutics Annual Data
Dec18 Dec19 Dec20
Cash-to-Debt 29.52 5.51 295.75

Keros Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.01 132.50 134.08 295.75 320.21

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Keros Therapeutics Cash-to-Debt Distribution

* The bar in red indicates where Keros Therapeutics's Cash-to-Debt falls into.



Keros Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Keros Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2020 is calculated as:

Keros Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2021 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keros Therapeutics  (NAS:KROS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Keros Therapeutics Cash-to-Debt Related Terms


Keros Therapeutics Cash-to-Debt Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)